BioCentury

7:00 AM GMT, Apr 11, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

REG1 Anticoagulation System: Phase IIb data

The double-blind reversal, active-controlled, international Phase IIb RADAR trial in 640 evaluable ACS patients undergoing cardiac catheterization showed that Regado's REG1 Anticoagulation System met 1 of 2 co-primary endpoints. On the first co-primary endpoint, the arm consisting of 100%

Read the full 394 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.